A Phase 3 interventional study of HX575 epoetin alfa Hexal AG and ERYPO®, Janssen-Cilag in Anemia, sponsored by Sandoz. Completed at 54 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-03.
Sponsored by Sandoz (formerly part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Anemia by Novartis — 1 open to participants now, 2 under way, 2 of them phase 3. Anemia · Novartis.
Among the 19 studies in Anemia by Novartis, this one is the 3rd largest by enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2004, is one of 12 in phase 3, and was the 5th registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →1 of the 19 studies in Anemia by Novartis is open now, in 6 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Brazil, Colombia and 3 more countries
Ages 2–18
By country, each count listing its studies:
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 478 is above the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 97 across the 17 interventional studies, 1,097 across the 2 observational. Of the 16 that completed or were terminated, 11 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Sandoz, one of the names counted as Novartis. Under that name alone:
Sandoz is the lead sponsor of 139 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.
1 of the studies in Anemia by Novartis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04747613Phase 3Novartis PharmaceuticalsLong-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria | 2027-10-18 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies in Anemia by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a double-blind, randomized, multicenter, parallel-group, equivalence study involving about 462 clinically stable hemodialysis patients aged 18 years or above suffering from anemia and treated previously with a stable dose of ERYPO® intravenously.
The primary objective of this Phase III study is the evaluation of therapeutic equivalence of HX575 Hexal AG and a comparator of epoetin alfa, ERYPO® in the maintenance intravenous treatment of renal anemia. Efficacy, dosage and safety of HX575 Hexal AG in the long-term treatment were assessed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eligible patients were switched from the comparator ERYPO®, to epoetin alfa HX575 Hexal AG in ratio 2:1 to be intravenously treated with HX575 in pre-filled syringes for 24 weeks (solution for injection i.v.). The maximum weekly dose was 300 UI/kg body weight (given 1 to 3 times) to maintain hemoglobin levels between 10-13 g/dL.
Drug: HX575 epoetin alfa Hexal AG
Eligible patients were randomized and continued to be treated with ERYPO® Janssen-Cilag in pre-filled syringes intravenously (solution for injection i.v.) for 24 weeks. The maximum weekly dose was 300 UI/kg body weight (given 1 to 3 times) to maintain hemoglobin levels between 10-13 g/dL.
Drug: ERYPO®, Janssen-Cilag
HX575 Solution for i.v. injection Containing 1000, 2000 and 4000 IU of rh erythropoietin
Also known as: Binocrit, Abseamed
Solution for i.v. injection
Also known as: EPREX®, Solution for i.v. injection
To Compare the Efficacy of HX575 Hexal AG and ERYPO® Janssen-Cilag.
Primary endpoint was the mean absolute change in Hb level between the screening/baseline and the evaluation period. A two-sided 95 % confidence interval for the difference in mean change (mean of evaluation period - mean of screening/baseline period) in Hb between epoetin alfa HX575 Hexal AG and ERYPO® Janssen-Cilag was computed. The difference was estimated from an analysis of a co-variance model including factors treatment, center, mean baseline Hb (\<11.5 and ≥11.5 g/dL) as factors and change of the mean weekly dose from screening/baseline to the evaluation period (of HX575 epoetin alfa Hexal AG or ERYPO® Janssen-Cilag) as a covariate. HX575 Hexal AG was considered at least as good as ERYPO® Janssen-Cilag if the 95 % confidence interval of the difference in mean changes in Hb levels between HX575 Hexal AG and ERYPO® Janssen-Cilag lied entirely within the interval \[-0.5 g/dL; 0.5 g/dL\]. Primary Endpoint was analyzed based on intent-to-treat (ITT) population.
Time frame: 28 weeks
Mean Absolute Change in Hemoglobin Level From the Screening/Baseline Period to the Evaluation Period - ITT Population
The mean absolute change in Hb levels between the screening/baseline period and the evaluation period was analyzed for the intent-to-treat (ITT) population in the same way as the primary efficacy endpoint. A two-sided 95 % confidence interval for the difference in mean change (mean of evaluation period - mean of screening/baseline period) in Hb between HX575 epoetin alfa Hexal AG and ERYPO® Janssen-Cilag was computed. The difference was estimated from an analysis of a co-variance model including factors treatment, center, mean baseline Hb (\<11.5 and ≥11.5 g/dL) as factors and change of the mean weekly dose from screening/baseline to the evaluation period (of HX575 epoetin alfa Hexal AG or ERYPO® Janssen-Cilag) as a covariate. HX575 Hexal AG was considered at least as good as ERYPO® Janssen-Cilag if the 95 % confidence interval of the difference in mean changes in Hb levels between HX575 Hexal AG and ERYPO® Janssen-Cilag lied entirely within the interval \[-0.5 g/dL; 0.5 g/dL\].
Time frame: 28 weeks
A total of 568 patients were screened. 479 were eligible for inclusion and were randomized. 478 patients were started on treatment with either epoetin alfa HX575 Hexal AG or ERYPO®, Janssen-Cilag. As the randomization followed a 2:1 scheme, 314 patients received HX575 Hexal AG and 164 patients received ERYPO®.
| Milestone | HX575 Epoetin Alfa Hexal AG | ERYPO®, Janssen-Cilag |
|---|---|---|
| Started | 314 | 164 |
| Completed | 261 | 142 |
| Not completed | 53 | 22 |
| Withdrew: Withdrawal by subject | 5 | 2 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Incl./excl. not fulfilled | 7 | 2 |
| Withdrew: Adverse event | 7 | 6 |
| Withdrew: Protocol violation | 2 | 0 |
| Withdrew: Death | 15 | 4 |
| Withdrew: Kidney transplantation (ntx) | 10 | 2 |
| Withdrew: Hemoglobulin concentration | 4 | 3 |
| Withdrew: Planned operation | 2 | 0 |
| Withdrew: Physician decision | 1 | 2 |
Primary endpoint was the mean absolute change in Hb level between the screening/baseline and the evaluation period. A two-sided 95 % confidence interval for the difference in mean change (mean of evaluation period - mean of screening/baseline period) in Hb between epoetin alfa HX575 Hexal AG and ERYPO® Janssen-Cilag was computed. The difference was estimated from an analysis of a co-variance model including factors treatment, center, mean baseline Hb (\<11.5 and ≥11.5 g/dL) as factors and change of the mean weekly dose from screening/baseline to the evaluation period (of HX575 epoetin alfa Hexal AG or ERYPO® Janssen-Cilag) as a covariate. HX575 Hexal AG was considered at least as good as ERYPO® Janssen-Cilag if the 95 % confidence interval of the difference in mean changes in Hb levels between HX575 Hexal AG and ERYPO® Janssen-Cilag lied entirely within the interval \[-0.5 g/dL; 0.5 g/dL\]. Primary Endpoint was analyzed based on intent-to-treat (ITT) population.
| g/dL | HX575 Epoetin Alfa Hexal AG | ERYPO®, Janssen-Cilag |
|---|---|---|
| To Compare the Efficacy of HX575 Hexal AG and ERYPO® Janssen-Cilag. | 0.147 ± 0.092 | 0.063 ± 0.117 |
The mean absolute change in Hb levels between the screening/baseline period and the evaluation period was analyzed for the intent-to-treat (ITT) population in the same way as the primary efficacy endpoint. A two-sided 95 % confidence interval for the difference in mean change (mean of evaluation period - mean of screening/baseline period) in Hb between HX575 epoetin alfa Hexal AG and ERYPO® Janssen-Cilag was computed. The difference was estimated from an analysis of a co-variance model including factors treatment, center, mean baseline Hb (\<11.5 and ≥11.5 g/dL) as factors and change of the mean weekly dose from screening/baseline to the evaluation period (of HX575 epoetin alfa Hexal AG or ERYPO® Janssen-Cilag) as a covariate. HX575 Hexal AG was considered at least as good as ERYPO® Janssen-Cilag if the 95 % confidence interval of the difference in mean changes in Hb levels between HX575 Hexal AG and ERYPO® Janssen-Cilag lied entirely within the interval \[-0.5 g/dL; 0.5 g/dL\].
| g/dL | HX575 Epoetin Alfa Hexal AG | ERYPO®, Janssen-Cilag |
|---|---|---|
| Mean Absolute Change in Hemoglobin Level From the Screening/Baseline Period to the Evaluation Period - ITT Population | 0.003 ± 0.079 | -0.187 ± 0.105 |
Collected over Recording of AEs included periods before first application and until the end of application of study medication. Occurrence of AEs was recorded from time when patient had given his/her informed consent until the final visit of the main study period (visit 28). By definition, AEs starting in the period after first application until the end of the main period were considered to be 'treatment-emergent' AEs. Analysis based on safety population: patients received at least 1 dose of treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HX575 Epoetin Alfa Hexal AG | 19/314 (6.1%) | 112/314 (35.7%) | 283/314 (90.1%) |
| ERYPO®, Janssen-Cilag | 5/164 (3%) | 57/164 (34.8%) | 154/164 (93.9%) |
| Event | HX575 Epoetin Alfa Hexal AG | ERYPO®, Janssen-Cilag |
|---|---|---|
| Cardiac and vascular procedural complicationsInjury, poisoning and procedural complications | 24/314 | 14/164 |
| Ischaemic coronary artery disordersCardiac disorders | 17/314 | 7/164 |
| Lower respiratory tract and lung infectionsInfections and infestations | 14/314 | 5/164 |
| Bacterial infections NECInfections and infestations | 8/314 | 1/164 |
| Peripheral vasoconstriction, necrosis and vascular insufficiencyVascular disorders | 8/314 | 2/164 |
| Sepsis, bacteraemia and viraemiaInfections and infestations | 7/314 | 1/164 |
| Rate and rhythm disorders NECCardiac disorders | 6/314 | 3/164 |
| Cholecystitis and cholelithiasisHepatobiliary disorders | 3/314 | 3/164 |
| Supraventricular arrhythmiasCardiac disorders | 5/314 | 0/164 |
| Accelerated and malignant hypertensionVascular disorders | 5/314 | 1/164 |
| Event | HX575 Epoetin Alfa Hexal AG | ERYPO®, Janssen-Cilag |
|---|---|---|
| Muscle spasmsMusculoskeletal and connective tissue disorders | 77/314 | 38/164 |
| NasopharyngitisInfections and infestations | 55/314 | 35/164 |
| DiarrhoeaGastrointestinal disorders | 63/314 | 22/164 |
| Haemodialysis-induced symptomInjury, poisoning and procedural complications | 49/314 | 23/164 |
| HypotensionVascular disorders | 48/314 | 20/164 |
| Procedural hypotensionInjury, poisoning and procedural complications | 44/314 | 23/164 |
| BronchitisInfections and infestations | 28/314 | 19/164 |
| VomitingGastrointestinal disorders | 27/314 | 18/164 |
| NauseaGastrointestinal disorders | 30/314 | 14/164 |
| HypertensionVascular disorders | 29/314 | 9/164 |
All randomized patients who received at least 1 dose of the study medication and for whom at least 1 post-baseline value of the primary endpoint Hb was available. A prerequisite for patients to be included in the Intention To Treat (ITT) population is that they were treated for four weeks with Hb values available during this period.
| Age, Categorical(Participants) | HX575 Epoetin Alfa Hexal AG | ERYPO®, Janssen-Cilag | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 145 | 84 | 229 |
| >=65 years | 169 | 80 | 249 |
| Age, Continuous(years) | HX575 Epoetin Alfa Hexal AG | ERYPO®, Janssen-Cilag | Total |
|---|---|---|---|
| Mean | 62.3 ± 14.4 | 62.6 ± 13.8 | 62.4 ± 14.2 |
| Sex: Female, Male(Participants) | HX575 Epoetin Alfa Hexal AG | ERYPO®, Janssen-Cilag | Total |
|---|---|---|---|
| Female | 138 | 98 | 236 |
| Male | 176 | 66 | 242 |
| Region of Enrollment(participants) | HX575 Epoetin Alfa Hexal AG | ERYPO®, Janssen-Cilag | Total |
|---|---|---|---|
| Austria | 70 | 37 | 107 |
| Germany | 244 | 127 | 371 |
| Body weight(kg) | HX575 Epoetin Alfa Hexal AG | ERYPO®, Janssen-Cilag | Total |
|---|---|---|---|
| Mean | 76.3 ± 15.5 | 76.0 ± 17.7 | 76.2 ± 16.2 |
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Apr 2004 to primary completion in Jan 2006, 21 months.
Results were first posted in Aug 2017, 11 years 7 months after primary completion.
Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 21 months is below that.
Counting every sponsor, half of 149 studies reached it within 30 months; a quarter within 17 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.